Synergistic anti-breast-cancer effects of combined treatment with oleuropein and doxorubicin in vivo

Alternative Therapies in Health and Medicine

Volumn 25, Issue 3, 2019, Pages 17-24

  Elamin, Maha H ^a   Elmahi, Abdelsalam B ^b   Daghestani, Maha H ^a   Al Olayan, Ebtesam M ^a   Al Ajmi, Reem A ^c   Alkhuriji, Afrah F ^c   Hamed, Sherifa S ^c,d   Elkhadragy, Manal F ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF KHARTOUM   (Sudan)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d Alexandria University Faculty Of Science   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; IRIDOID; OLEUROPEIN;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BREAST TUMOR; CELL PROLIFERATION; FEMALE; HUMAN; MOUSE; NUDE MOUSE; TUMOR CELL LINE; TUMOR RECURRENCE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; FEMALE; HUMANS; IRIDOIDS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL;

EID: 85067201978     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics. CA Cancer J Clin. 2008;58:71-96.
2. Weigelt B, Peterse JL, van’t Veer LJ. Breast cancer metastasis: Markers and models. Nat Rev Cancer. 2005;5:591-602.
3. De Lorgeril M, Salen P, Martin JL, Monjaud I, Boucher P, Mamelle N. Mediterranean dietary pattern in a randomized trial: Prolonged survival and possible reduced cancer rate. Arch Intern Med. 1998;158:1181-1187.
4. Keys A, Aravanis C, Blackburn H, et al. Serum cholesterol and cancer mortality in the Seven Countries Study. Am J Epidemiol. 1985;121:870-883.
5. Renaud S, de Lorgeril M, Delaye J, et al. Mediterranean diet for prevention of coronary heart disease. Am J Clin Nutr. 1995;61:1360S-1367S.
6. Reedy J, Krebs-Smith SM, Miller PE, et al. Higher diet quality is associated with decreased risk of all-cause, cardiovascular disease, and cancer mortality among older adults. J Nutr. 2014;144: 881-889.
7. Trichopoulou A, Lagiou P, Kuper H, Trichopoulos D. Cancer and Mediterranean dietary traditions. Cancer Epidemiol Biomarkers Prev. 2000;9:869-873.
8. Han J, Talorete T, Yamada P, Isoda H. Anti-proliferative and apoptotic effects of oleuropein and hydroxytyrosol on human breast cancer MCF-7 cells. Cytotechnology. 2009;59:45-53.
9. Gutierrez-Rosales F, Rios JJ, Gomez-Rey ML. Main polyphenols in the bitter taste of virgin olive oil: Structural confirmation by on-line high-performance liquid chromatography electro-spray ionization mass spectrometry. J Agric Food Chem. 2003;51:6021-6025.
10. Bonoli M, Bendini A, Cerretani L, Lercker G, Toschi TG. Qualitative and semiquantitative analysis of phenolic compounds in extra virgin olive oils as a function of the ripening degree of olive fruits by different analytical techniques. J Agric Food Chem. 2004;52:7026-7032.
11. Ozdemir Y, Guven E, Ozturk A. Understanding the characteristics of oleuropein for table olive processing. J Food Process Technol. 2014;5:328-333.
12. Carluccio MA, Siculella L, Ancora MA, et al. Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol. 2003;23:622-629.
13. Omar SH. Oleuropein in olive and its pharmacological effects. Sci Pharm. 2010;78:133-154.
14. Visioli F, Poli A, Gall C. Antioxidant and other biological activities of phenols from olives and olive oil. Med Res Rev. 2002;22:65-75.
15. Elamin MH, Daghestani MH, Omer SA, et al. Olive oil oleuropein has anti-breast cancer properties with higher efficiency on ER-negative cells. Food Chem Toxicol. 2013;53:310-316.
16. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57:727-741.
17. Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin Cardiomyopathy. Cardiology. 2010;115:155-162.
18. Haffner MC, Berlato C, Doppler W. Exploiting our knowledge of NF-kappa B signaling for the treatment of mammary cancer. J Mammary Gland Biol Neoplasia. 2006;11:63-73.
19. Karczmarek-Borowska B, Filip A, Wojcierowski J, et al. Survivin antiapoptotic gene expression as a prognostic factor in non-small-cell lung cancer: In situ hybridization study. Folia Histochem Cytobiol. 2005;43:237-242.
20. Altieri DC. Survivin cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8:61-70.
21. Kimura Y, Sumiyoshi M. Olive leaf extract and its main component oleuropein prevent chronic ultraviolet B radiation-induced skin damage and carcinogenesis in hairless mice. J Nut. 2009;139:2079-2086.
22. Del Boccio P, Di Deo A, De Curtis A, Celli N, Iacoviello L, Rotilio D. Liquid chromatography-tandem mass spectrometry analysis of oleuropein and its metabolite hydroxytyrosol in rat plasma and urine after oral administration. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;785:47-56.
23. Hamdi KH, Castellon R. Oleuropein, a non-toxic olive iridoid, is an anti-tumor agent and cytoskeleton disruptor. Biochem and Biophysical Res Com. 2005;334:769-778.
24. Santiago-Mora R, Casado-Diaz A, De Castro MD, Quesada-Gomez JM. Oleuropein enhances osteoblastogenesis and inhibits adipogenesis: The effect on differentiation in stem cells derived from bone marrow. Osteoporos Int. 2011;22:675-684.
25. Sirianni R, Chimento A, De Luca A, et al. Oleuropein and hydroxytyrosol inhibit MCF-7 breast cancer cell proliferation interfering with ERK1/2 activation. Mol Nutr Food Res. 2010;54:833-840.
26. Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma1. Mol Cancer Ther. 2003;2:617-622.
27. Lindholm EM, Kristian A, Nalwoga H, et al. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal-and luminal-like breast cancer xenografts. Molecular Oncology. 2012;6:418-427.
28. Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs. 1997;15:39-48.
29. Honstvet CA, Jones PF. Targeting tumor vasculature as a cancer treatment. Comput Math Methods Med. 2007;8:1-9.
30. McLoon LK, Falkenberg JH, Dykstra D, Iaizzo PA. Doxorubicin chemomyectomy as a treatment for cervical dystonia: Histological assessment after direct injection into the sternocleidomastoid muscle. Muscle Nerve. 1998;21:1457-1464.
31. Bagriacik EU, Uslu K, Yurtcu E, Stefek M, Karasu C. Stobadine inhibits doxorubicin-induced apoptosis through a caspase-9 dependent pathway in P815 mastocytoma cells. Cell Biol Int. 2007;31:979-984.
32. Rogalska A, Gajek A, Szwed M, Jozwiak Z, Marczak A. The role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: A comparison with the effect of doxorubicin. Toxicol In Vitro. 2011;25:1712-1720.
33. Brumi G, Carbonei T, Stilli E, et al. N-acetylcysteine potentiates doxorubicin-induced ATM and p53 activation in ovarian cancer cells. Int J Oncol. 2013;42:211-218.
34. Gourlay CW, Ayscough KR. The actin cytoskeleton: A key regulator of apoptosis and ageing? Nat Rev Mol Cell Biol. 2005;6:583-589.
35. Bijman MN, van Berkel MP, van Nieuw Amerongen GP, Boven E. Interference with actin dynamics is superior to disturbance of microtubule function in the inhibition of human ovarian cancer cell motility. Biochem Pharmacol. 2008;76:707-716.
36. Ashley N, Poulton J. Anticancer DNA intercalators cause p53-dependent mitochondrial DNA nucleoid re-modelling. Oncogene. 2009;28:3880-3891.
37. Lee CH, Jeon YT, Kim SH, Song YS. NF-kappaB as a potential molecular target for cancer therapy. Biofactors. 2007;29:19-35.
38. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ. 2006;13:738-747.
39. Orlowski RZ, Baldwin AS. NF-kappa B as a therapeutic target in cancer. Trends Mol Med. 2002;8:385-389.
40. Ouyang W, Li J, Ma Q, Huang C. Essential roles of PI3K/Akt/IKKbeta/ NFkappaB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis. 2006;27:864-873.
41. Velasco-Velázquez MA, Li Z, Casimiro M, Loro E, Homsi N, Pestell RG. Examining the role of cyclin D1 in breast cancer. Future Oncol. 2011;7:753-765.
42. Harris RE, Casto BC, Harris ZM. Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol. 2014;5:677-692.
43. Holmes MD, Chen WY, Schnitt SJ, Collins L, Colditz GA, Hankinson SE, Tamimi RM. Cox-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat. 2011;130:657-662.
44. Tanaka K, Iwamoto So, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127-134.
45. Tanaka K, Iwamoto So, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127-134.
46. Jha K, Shukla M, Pandey M. Survivin expression and targeting in breast cancer. Surg Oncol. 2012;21:125-131.
47. Lacroix M, Toillon R, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer. 2006;13:293-325.
48. Dotto GP. p21(WAF1/Cip1): More than a break to the cell cycle? Biochim Biophys Acta. 2000;1471:43-56.
49. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 2002;1:639-649.
50. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010;176:2911-2920.
51. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: Disease entity or title of convenience? Nat Rev Clin Oncol. 2010;17:683-692.
52. Shi Y, Moon M, Dawood S, McManus B, Liu PP. Mechanisms and management of doxorubicin cardiotoxicity. Herz. 2011;36:296-305.